Author:
Correale Jorge,Flores Jose,Bonitto Juan Garcia,Rodríguez Claudia Cárcamo,Oliveira Enedina M. L.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference63 articles.
1. US Food and Drug Administration. Gilenya® (fingolimod) prescribing information; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022527s009lbl.pdf . Accessed June 16, 2014.
2. Novartis Pharma AG. Data on file. 2015.
3. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56.
4. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.
5. Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献